Literature DB >> 34386857

Antineoplastic agents aggravate the damages caused by nicotine on the peri-implant bone: an in vivo histomorphometric and immunohistochemical study in rats.

Juliano Milanezi de Almeida1,2, Edilson Ervolino3,4, David Jonathan Rodrigues Gusman5,3, Luiz Guilherme Fiorin5,3, Breno Edson Sendão Alves5,3, Fernando Pozzi Semeghini Guastaldi6, Henrique Rinaldi Matheus5,3.   

Abstract

OBJECTIVE: To assess the interaction between chemotherapy and normal tissues is critical to assure quality of life during and after the treatment of cancer. This study evaluated the influence of cisplatin (CIS) and 5-fluorouracil (5-FU) over the peri-implant tissues around osseointegrated titanium implants in animals previously exposed to nicotine. Materials and methods One hundred twenty male rats were divided into two groups, receiving via subcutaneous injection, either physiological saline solution (PSS) (n = 30) or nicotine hemissulfate (NIC) (n = 90) for 30 days prior to implants' placement. One titanium implant (4.0 × 2.2 mm) was installed in each tibia of all animals. PSS and NIC were continued for 30 days after surgery. Five days after cessation, rats were subdivided into three subgroups in accordance with systemic treatments with either PSS, CIS, or 5-FU. Euthanasia was performed at 50, 65, and 95 days post-surgery. Histometric, histopathological, and immunohistochemical analyses were performed.
RESULTS: NIC-CIS and NIC-5FU presented lower BIC (50, 65, and 95 days) and bone area fraction occupancy (BAFO) (65 and 95 days) than group NIC. Intense inflammatory infiltration, severe tissue breakdown, reduced expression of bone formation biomarkers, and upregulation of TRAP were observed in NIC-CIS and NIC-5FU when compared with group NIC. TRAP expression was significantly higher in NIC-5FU as compared with NIC-CIS at 50 and 95 days. Groups NIC, NIC-CIS, and NIC-5FU presented statistically significant negative impact in all outcome parameters than group PSS.
CONCLUSION: CIS and 5-FU severely disrupted the peri-implant tissues around osseointegrated implants in animals previously exposed to nicotine. CLINICAL RELEVANCE: Assessing the interaction between chemotherapy and normal tissues is critical to assure quality of life during and after the cancer treatment.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Antineoplastic agents; Cisplatin; Dental implants; Fluorouracil; Nicotine; Osseointegration

Mesh:

Substances:

Year:  2021        PMID: 34386857     DOI: 10.1007/s00784-021-04121-1

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.606


  48 in total

1.  Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

Authors:  Jochen H Lorch; Olga Goloubeva; Robert I Haddad; Kevin Cullen; Nicholas Sarlis; Roy Tishler; Ming Tan; John Fasciano; Daniel E Sammartino; Marshall R Posner
Journal:  Lancet Oncol       Date:  2011-01-11       Impact factor: 41.316

Review 2.  Cellular processing of platinum anticancer drugs.

Authors:  Dong Wang; Stephen J Lippard
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

3.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

Authors:  Kristian Pietras; Douglas Hanahan
Journal:  J Clin Oncol       Date:  2004-11-22       Impact factor: 44.544

4.  New paradigms and future challenges in radiation oncology: an update of biological targets and technology.

Authors:  Stanley L Liauw; Philip P Connell; Ralph R Weichselbaum
Journal:  Sci Transl Med       Date:  2013-02-20       Impact factor: 17.956

5.  Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.

Authors:  André B P van Kuilenburg; Rutger Meinsma; Bernard A Zonnenberg; Lida Zoetekouw; Frank Baas; Koichi Matsuda; Nanaya Tamaki; Albert H van Gennip
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

Review 6.  5-fluorouracil: mechanisms of action and clinical strategies.

Authors:  Daniel B Longley; D Paul Harkin; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

Review 7.  Tobacco carcinogens, their biomarkers and tobacco-induced cancer.

Authors:  Stephen S Hecht
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

8.  Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.

Authors:  Jeong-Min Cho; Sarala Manandhar; Hyang-Rim Lee; Hyun-Min Park; Mi-Kyoung Kwak
Journal:  Cancer Lett       Date:  2007-11-26       Impact factor: 8.679

9.  Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).

Authors:  J B Vermorken; F Peyrade; J Krauss; R Mesía; E Remenar; T C Gauler; U Keilholz; J P Delord; P Schafhausen; J Erfán; T H Brümmendorf; L Iglesias; U Bethe; C Hicking; P M Clement
Journal:  Ann Oncol       Date:  2014-03       Impact factor: 32.976

10.  Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses.

Authors:  Hirokazu Urushiyama; Taisuke Jo; Hideo Yasunaga; Nobuaki Michihata; Hiroki Matsui; Wakae Hasegawa; Hideyuki Takeshima; Yukiyo Sakamoto; Yoshihisa Hiraishi; Akihisa Mitani; Kiyohide Fushimi; Takahide Nagase; Yasuhiro Yamauchi
Journal:  Cancer Med       Date:  2018-08-27       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.